329 related articles for article (PubMed ID: 28246276)
1. Interplay between Immune Checkpoint Proteins and Cellular Metabolism.
Lim S; Phillips JB; Madeira da Silva L; Zhou M; Fodstad O; Owen LB; Tan M
Cancer Res; 2017 Mar; 77(6):1245-1249. PubMed ID: 28246276
[TBL] [Abstract][Full Text] [Related]
2. The cancer metabolic reprogramming and immune response.
Xia L; Oyang L; Lin J; Tan S; Han Y; Wu N; Yi P; Tang L; Pan Q; Rao S; Liang J; Tang Y; Su M; Luo X; Yang Y; Shi Y; Wang H; Zhou Y; Liao Q
Mol Cancer; 2021 Feb; 20(1):28. PubMed ID: 33546704
[TBL] [Abstract][Full Text] [Related]
3. Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.
Smolle MA; Calin HN; Pichler M; Calin GA
FEBS J; 2017 Jul; 284(13):1952-1966. PubMed ID: 28132417
[TBL] [Abstract][Full Text] [Related]
4. The influence of microenvironment on tumor immunotherapy.
Zhang J; Shi Z; Xu X; Yu Z; Mi J
FEBS J; 2019 Nov; 286(21):4160-4175. PubMed ID: 31365790
[TBL] [Abstract][Full Text] [Related]
5. T cell metabolic fitness in antitumor immunity.
Siska PJ; Rathmell JC
Trends Immunol; 2015 Apr; 36(4):257-64. PubMed ID: 25773310
[TBL] [Abstract][Full Text] [Related]
6. Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.
Rivadeneira DB; Delgoffe GM
Clin Cancer Res; 2018 Jun; 24(11):2473-2481. PubMed ID: 29386217
[TBL] [Abstract][Full Text] [Related]
7. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.
Mediavilla-Varela M; Castro J; Chiappori A; Noyes D; Hernandez DC; Allard B; Stagg J; Antonia SJ
Neoplasia; 2017 Jul; 19(7):530-536. PubMed ID: 28582704
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
El Sayed R; Haibe Y; Amhaz G; Bouferraa Y; Shamseddine A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670011
[TBL] [Abstract][Full Text] [Related]
9. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
10. Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.
Ho PC; Kaech SM
Curr Opin Immunol; 2017 Jun; 46():38-44. PubMed ID: 28458087
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy in lung cancer: New concepts].
Goubet AG; Livartowski A; Romano E
Rev Mal Respir; 2018 Jun; 35(6):642-651. PubMed ID: 29941206
[TBL] [Abstract][Full Text] [Related]
12. TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy.
Huang L; Xu H; Peng G
Cell Mol Immunol; 2018 May; 15(5):428-437. PubMed ID: 29553135
[TBL] [Abstract][Full Text] [Related]
13. Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy.
Cerezo M; Rocchi S
Cell Death Dis; 2020 Nov; 11(11):964. PubMed ID: 33177494
[TBL] [Abstract][Full Text] [Related]
14. Metabolites in the Tumor Microenvironment Reprogram Functions of Immune Effector Cells Through Epigenetic Modifications.
Li Y; Wu Y; Hu Y
Front Immunol; 2021; 12():641883. PubMed ID: 33927716
[TBL] [Abstract][Full Text] [Related]
15. Microenvironmental Metabolism Regulates Antitumor Immunity.
Ngwa VM; Edwards DN; Philip M; Chen J
Cancer Res; 2019 Aug; 79(16):4003-4008. PubMed ID: 31362930
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
Tsai HF; Hsu PN
J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
[TBL] [Abstract][Full Text] [Related]
17. A model for tumor-immune interaction.
de Souza N
Nat Methods; 2018 Oct; 15(10):762. PubMed ID: 30275589
[No Abstract] [Full Text] [Related]
18. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy.
Yin Z; Bai L; Li W; Zeng T; Tian H; Cui J
J Exp Clin Cancer Res; 2019 Sep; 38(1):403. PubMed ID: 31519198
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
Ramsay AG
Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
[TBL] [Abstract][Full Text] [Related]
20. Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy.
Sheppard AD; Lysaght J
Methods Mol Biol; 2020; 2184():233-263. PubMed ID: 32808230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
